<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Because topiramate (TPM) suppresses voltage-sensitive <z:chebi fb="1" ids="29101">Na+</z:chebi> channels and non-<z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptors and enhances <z:chebi fb="0" ids="16865">gamma-aminobutyric acid</z:chebi> (<z:chebi fb="3" ids="16865">GABA</z:chebi>)-mediated inhibition, we tested whether it would protect against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The right middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) was embolized by an intra-arterial injection of autogenous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two hours after <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> injection, animals received intra-peritoneal injections (i.p.) of <z:mpath ids='MPATH_458'>normal</z:mpath> saline as control (n=6) or alternatively, a low- (20 mg/kg, i.p., n=6) or high-dose (40 mg/kg, i.p., n=6) of TPM </plain></SENT>
<SENT sid="3" pm="."><plain>Neurological deficit was scored at 2 h and 24 h following the ischemic insult </plain></SENT>
<SENT sid="4" pm="."><plain>The animals were sacrificed 24 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and the coronal brain sections were stained with 2% 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) for determination of the percentage of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of TPM significantly improved the 24-h neurological deficit scores (low dose, 1.75+/-0.5; high dose, 1.17+/-0.41; p&lt;0.05 for both doses) </plain></SENT>
<SENT sid="6" pm="."><plain>A reduction in the percentage of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (low dose, 22.9+/-8.9%, p=0.002; high dose 7.6+/-3.4%, p&lt;0.001) was seen when compared to the controls (<z:mpath ids='MPATH_124'>infarct</z:mpath> size, 54.2+/-9.0%; neurobehavior score, 2 </plain></SENT>
<SENT sid="7" pm="."><plain>67+/-0.52) </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with TPM at the higher dose induced more neuroprotection than that at the lower dose (p&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, treatment with TPM resulted in a dose- and use-dependent neuroprotective effect, when used 2 h after <z:chebi fb="70" ids="34342">MCA</z:chebi> embolization in a rat model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>